Banerji, U, Dean, E J, Alejandro Perez-Fidalgo, J, Batist, G, Bedard, P L, You, B, Westin, S N, Kabos, P, Garrett, M D, Tall, M, Ambrose, H, Carl Barrett, J, Hedley Carr, T, Amy Cheung, S Y, Corcoran, C, Cullberg, M, Davies, B R, de Bruin, E C, Elvin, P, Foxley, A, Lawrence, P, Lindemann, J P O, Maudsley, R, Pass, M, Rowlands, V, Rugman, P, Schiavon, G, Yates, J & Schellens, J H M 2018, ' A phase i open-label study to identify a dosing regimen of the pan-akt inhibitor azd5363 for evaluation in solid tumors and in pik3ca-mutated breast and gynecologic cancers ', Clinical Cancer Research, vol. 24, no. 9, pp. 2050-2059 . https://doi.org/10.1158/1078-0432.CCR-17-2260 Clinical Cancer Research, 24(9), 2050. American Association for Cancer Research Inc.
Searle, E, Telfer, B, Mukherjee, D, Forster, D, Davies, B R, Williams, K, Stratford, I & Illidge, T 2017, ' Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment ', EMBO Molecular Medicine, vol. 9, no. 12, pp. 1646-1659 . https://doi.org/10.15252/emmm.201707767